HK Stock Market Move | SIHUAN PHARM (00460) rose more than 6% during intraday trading. Clinical research on Xuanzhu Biologics, an affiliate, showed prominent survival data in late-stage breast cancer treatment.

SIHUAN PHARM (00460) rose more than 6% in midday trading, and as of the time of writing, it was up 4.92% at HK$0.64, with a total trading volume of HK$104.181 million. On the news front, SIHUAN PHARM announced a major scientific breakthrough for its innovative drug "Pilorin" developed by its non-wholly-owned subsidiary Xuanzhu Bio. The interim analysis results of the Phase III clinical study of Pilorin in combination with Fluvisumab for the treatment of HR+/HER2- advanced breast cancer have been officially published in the top-tier journal Nature Communications. The announcement stated that the combination of Pilorin and Fluvisumab showed significant efficacy. Particularly, it significantly reduced the risk for patients with primary endocrine resistance, simple bone metastasis, and liver metastasis, and it was able to shrink the tumor, relieve symptoms, and bring survival benefits. In this study, Pilorin demonstrated outstanding survival data in the face of a more complex population and more difficult disease challenges.